Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome (HOT-LoCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04842448
Recruitment Status : Recruiting
First Posted : April 13, 2021
Last Update Posted : September 22, 2021
Sponsor:
Collaborators:
Karolinska Institutet
Karolinska Trial Alliance
EDC Scandinavia AB
Information provided by (Responsible Party):
Anders Kjellberg, MD, Karolinska University Hospital

Brief Summary:

Long COVID Syndrome (Long COVID), Post Acute COVID-19 Syndrome (PACS) or Post COVID-19 Syndrome (PCS) is defined as 'signs and symptoms that develop during or following an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis'. 1 in 10 infected individuals may suffer persistent symptoms, and we are facing an emerging problem that will severely affect individuals, health care systems and society for years to come.

We explore hyperbaric oxygen administered in a randomized placebo-controlled clinical trial as a potential treatment for patients suffering from Long COVID.

The overall hypothesis to be evaluated is that hyperbaric oxygen (HBO2) alleviates symptoms associated with Long COVID.


Condition or disease Intervention/treatment Phase
COVID-19 Drug: Hyperbaric oxygen Procedure: Sham treatment Phase 2

Detailed Description:

Phase II Clinical Trial

Prospective randomized, placebo-controlled, double blind, phase II, clinical trial, estimated enrolment: 80 subjects Parallel groups Intervention: HBO2: 240 kPa for 90 min, maximum 10 treatments within 6 weeks from randomization

Control: Placebo treatment with 'sham' air breathing at a moderately higher pressure (134 kPa) to simulate hyperbaric chamber treatment, maximum 10 treatments within 6 weeks from randomization

The population will comprise of previously healthy patients (American Society of Anaesthesiologists (ASA) class 1-2 diagnosed with Long COVID (U09.9) by a multidisciplinary team. All patients are assessed with a battery of questionnaires, physical tests, laboratory tests and radiology. After their first assessment, individuals may have further organ specific work up for diagnosis, such as diagnosis of Postural Orthostatic Tachycardia Syndrome (POTS).

Once the patient has been diagnosed with Long COVID, they will be informed and asked to participate in the trial. No study specific procedures will take place before an informed consent form (ICF) has been signed. The patients will be included once they fulfil the inclusion criteria and exhibit none of the exclusion criteria. Some study specific procedures will be performed before inclusion. Eligible subjects will be randomized within two weeks of the planned first treatment. Subjects will be randomized in a 1:1 allocation to HBO2 or placebo (sham treatment). Scheduling of the HBOT will depend on available resources but the first treatment should be given within two weeks after randomization, and a maximum ten treatments should be given within 6 weeks from randomization.

Clinical equipoise: The rationale for 1:1 randomization is that this is a new disease and that it will maximise the statistical power to detect a statistically significant efficacy between treatment groups.

Main efficacy and safety endpoints will be evaluated at three months but the trial will continue for one year after inclusion or until withdrawal. There will also be a four year post-trial follow up of health-economy.

The trial will be conducted in compliance with Good Clinical Practice (GCP), the Declaration of Helsinki and national regulatory requirements.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, placebo-controlled, double-blind, phase II
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Subjects will be randomized to either active treatment or sham treatment. Assessors will be blinded to treatment group.
Primary Purpose: Treatment
Official Title: Hyperbaric Oxygen for Treatment of Long COVID Syndrome; A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial
Actual Study Start Date : September 15, 2021
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Hyperbaric oxygen treatment
HBO2 240 kPa, 90 min, maximum 10 treatments
Drug: Hyperbaric oxygen
Hyperbaric oxygen 240 kPa for 90 minutes (with 10 min compression time, 2 air bakes and 10 minutes decompression time).
Other Names:
  • HBO
  • HBO2
  • HBOT

Placebo Comparator: Sham treatment
Air 134-120 kPa, 90 min, maximum 10 treatments
Procedure: Sham treatment
Sham treatment 134-120 kPa Air (with 5 min compression time, and 5 min decompression to 120 kPa, two air brakes will be reported to the subjects)
Other Name: Placebo




Primary Outcome Measures :
  1. RAND 36 change [ Time Frame: Baseline and 13 weeks ]

    Mean change from baseline to 13 weeks in RAND 36 domains role limitations due to physical health (RP) and physical functioning (PF).

    RAND 36 is a self-reporting questionnaire that contains 36 items that measure eight concepts of health in general terms, at present and past four weeks. Numeric values from the survey are coded so that all items are scored from 0 (lowest score) to 100 (highest possible score). Scores then represent the percentage of total possible score achieved. Items in the same scale are averaged together to create the eight scale scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Hence, scale scores represent the average for all items in the scale that the respondent answered.



Secondary Outcome Measures :
  1. Endothelial dysfunction [ Time Frame: Baseline and 13 weeks ]
    Mean change from baseline to 13 weeks in Reactive Hyperemia Index (RHI)

  2. 6-min walk test [ Time Frame: Baseline and 13 weeks ]
    Mean change from baseline to 13 weeks in the 6-min walk test

  3. 30/60 min chair stand [ Time Frame: Baseline and 13 weeks ]
    Mean change from baseline to 13 weeks in the 30/60 sec chair stand

  4. EQ-5D [ Time Frame: Baseline and 13 weeks ]

    Mean change from baseline to 13 weeks in EQ-5D.

    EuroQol-5 Dimensions questionnaire is a widely used self-reporting questionnaire that measure 5 dimensions of health TODAY at three or five levels (EQ-5D-3L or EQ-5D-5L) of severity; no problems, some/moderate problems and extreme problems/unable.The health dimensions are mobility, self-care, usual activities, pain/discomfort, anxiety/depression and a visual analogue scale (VAS) 0-100 which it used as a quantitative measure of overall health status. EQ-5D is the most widely used questionnaire for health-economic evaluation.


  5. RAND 36 normalization [ Time Frame: Baseline and 13 weeks ]
    Proportion of subjects with a normalisation of levels in RAND-36 domains role limitations due to physical health and physical functioning respectively, at 13 weeks.


Other Outcome Measures:
  1. Adverse Events (AE) [ Time Frame: Baseline and 13 weeks ]
    Number of AEs at 13 weeks.

  2. Compliance [ Time Frame: Baseline and 13 weeks ]
    Number of subjects, proportion of subjects that have completed planned treatments and number of treatments after 6 weeks.

  3. RAND 36 longitudinal [ Time Frame: Baseline, 13 weeks, 26 weeks and 52 weeks ]
    Mean change in other RAND 36 domains at 13, 26 and 52 weeks compared to baseline.

  4. EQ-5D Health economy [ Time Frame: Baseline, 6 weeks, 26 weeks and 52 weeks ]
    Mean change in EQ-5D at 6, 26 and 52 weeks compared to baseline.

  5. Physical activity [ Time Frame: Baseline, 6 weeks, 13 weeks and 26 weeks ]
    Mean change in physical activity using an activity meter at 6, 13 and 26 weeks compared to baseline

  6. Heart Rate Variability (HRV) [ Time Frame: Baseline, 6 weeks, 13 weeks and 26 weeks ]
    Mean change in HRV using an activity meter at 6, 13 and 26 weeks compared to baseline

  7. Restorative sleep [ Time Frame: Baseline, 6 weeks, 13 weeks and 26 weeks ]
    Mean change in sleeping pattern using an activity meter at 6, 13 and 26 weeks compared to baseline.

  8. Hypoxia response [ Time Frame: Baseline, 6 weeks, 13 weeks and 26 weeks ]
    Mean change from baseline in hypoxia pathways in PBMCs evaluated by RNA sequencing, at 6, 13 and 26 weeks.

  9. Inflammatory response [ Time Frame: Baseline, 6 weeks, 13 weeks and 26 weeks ]
    Mean change from baseline in inflammatory pathways in PBMCs evaluated by RNA sequencing, at 6, 13 and 26 weeks

  10. Redox status [ Time Frame: Baseline, 6 weeks and 13 weeks ]
    Mean change from baseline of reactive oxygen species in red blood cells measured by Electron paramagnetic resonance spectroscopy (EPR) at 6 and 13 weeks.

  11. Long term follow-up RAND-36 [ Time Frame: Baseline, 26 weeks and 52 weeks ]
    Long-term follow up of change in HRQoL with self-reported questionnaire RAND-36

  12. Health-economic evaluation [ Time Frame: Baseline, 13 weks, 26 weeks and 52 weeks ]
    Economical cost/benefit evaluation using EQ-5D as variable

  13. microRNA [ Time Frame: Baseline, 6 weeks and 13 weeks ]
    Mean change from baseline of microRNA in plasma, at 6 and 13 weeks.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Aged 18-60 years
  2. Healthy or mild systemic disease (ASA 1-2) prior to COVID-19
  3. Symptoms consistent with Long COVID for at least 12 weeks
  4. Diagnosed with Long COVID, PACS, PCS (ICD-10 U09.9)
  5. Working or studying prior to COVID-19
  6. Documented informed consent according to GCP and national regulations

Exclusion Criteria:

  1. Known pregnancy or positive pregnancy test in women of childbearing age
  2. ASA 3 or more from other cause than Long COVID
  3. Score above 70 in RAND-36 Role Limitation Physical Health (RP) or Physical Functioning (PF)
  4. Diabetes
  5. Diagnosed with hypertension prior to COVID-19
  6. Contraindication for hyperbaric oxygen treatment according to local guidelines
  7. Participation or recent participation in a clinical trial with an investigational product
  8. Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04842448


Contacts
Layout table for location contacts
Contact: Anders Kjellberg, MD 0760657355 anders.kjellberg@ki.se

Locations
Layout table for location information
Sweden
Karolinska University Hospital Recruiting
Stockholm, Sweden, 171 76
Contact: Hyperbaric unit    +46812394680      
Contact: Anders Kjellberg, MD    +46851775212    anders.kjellberg@ki.se   
Principal Investigator: Anders Kjellberg, MD         
Sub-Investigator: Adrian Hassler, MD         
Sponsors and Collaborators
Karolinska University Hospital
Karolinska Institutet
Karolinska Trial Alliance
EDC Scandinavia AB
Investigators
Layout table for investigator information
Principal Investigator: Anders Kjellberg, MD Karolinska University Hospital (and Karolinska Insitutet)
Study Chair: Judith Bruchfeld, MD, PhD Karolinska University Hospital (and Karolinska Insitutet)
Study Chair: Malin Nygren-Bonnier, PhD Karolinska University Hospital (and Karolinska Insitutet)
Study Chair: Michael Runold, MD, PhD Karolinska University Hospital (and Karolinska Insitutet)
Study Chair: Marcus Ståhlberg, MD, PhD Karolinska University Hospital (and Karolinska Insitutet)
Study Chair: Peter Lindholm, MD, PhD Karolinska Insitutet
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Anders Kjellberg, MD, ICU Consultant, head of hyperbaric medicine, Karolinska University Hospital
ClinicalTrials.gov Identifier: NCT04842448    
Other Study ID Numbers: HOT-LoCO
2021-000764-30 ( EudraCT Number )
K 2021-1592 ( Other Identifier: Karolinska University Hospital )
4-621/2021 ( Other Identifier: Karolinska Institutet )
First Posted: April 13, 2021    Key Record Dates
Last Update Posted: September 22, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The full study protocol, statistical plan and consent form will be publicly available. Data will be available on patient level; data will be pseudonymized, the full dataset and statistical code will be available upon request.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: 6 months after study completion and for 36 months
Access Criteria: A full description of the intended use of the data must be sent to the corresponding author for review and approval. Participant consent for data sharing is conditioned and new ethics approval may be required.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Anders Kjellberg, MD, Karolinska University Hospital:
Long COVID
Post COVID Syndrome
COVID-19
Hyperbaric Oxygen
HBOT
Health Related Quality of Life
Endothelial dysfunction
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases